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Letters
High-Level Ciprofloxacin Resistance
in Neisseria gonorrhoeae:
First Report from Israel
To the Editor: We report a case of male gonococ-
cal urethritis that persisted despite
ciprofloxacin therapy. The isolate was found to
be highly resistant (MIC 32 µg/mL).
A 30-year-old man visited his family physi-
cian with a 2-day history of urethral discharge
and dysuria. The symptoms began 7 days after
a single, unprotected orogenital contact with a
female hitchhiker. The patient denied exchange
of money for the act and reported no other
recent sex partners or travel outside Israel.
After a urethral swab was obtained for culture,
the patient received a single dose of
ciprofloxacin (500 mg orally). Growth of Neis-
seria gonorrhoeae was subsequently reported.
However, symptoms persisted, and a regimen of
doxycycline (100 mg orally twice a day for 10
days) was initiated. After temporary clinical
improvement, the patient returned with wors-
ening symptoms: bloody urethral discharge,
severe dysuria, edema of the penis, and painful
erection. N. gonorrhoeae was reisolated from a
repeat urethral swab. When a single dose of
ceftriaxone (250 mg) was administered intra-
muscularly, clinical cure was prompt.
Susceptibility testing was performed on the
second isolate by using the E-test method (AB
Biodisk, Solna, Sweden) on a medium contain-
ing GC agar base and 1% defined growth
supplement. The MIC of ciprofloxacin was
32 µg/mL, penicillin 1.5 µg/mL, tetracycline
2 µg/mL, and ceftriaxone 0.016 µg/mL. The
isolate did not produce beta-lactamase. It was
classified as a CMRNGPT phenotype
(N. gonorrhoeae with chronomosomally
mediated resistance to both penicillin and
tetracycline).
Gonorrhea was considered a rare disease in
Israel in the 1990s: the average annual inci-
dence was 0.89 reported cases per 100,000
population (1). Most laboratories did not carry
appropriate media, and susceptibility testing of
N. gonorrhoeae was not performed routinely.
Quinolones and spectinomycin are the antibiot-
ics most commonly used to treat the infection.
Nevertheless, we are not aware of any instance
of clinical failure following fluoroquinolone
therapy. More recently, however, the incidence
of gonorrhea has been increasing (2). In re-
sponse, a surveillance program for monitoring
antimicrobial resistance in N. gonorrhoeae has
been launched.
Fluoroquinolones and cephalosporins
became the recommended drugs for treatment
of gonococcal infection after penicillin- and
tetracycline-resistant N. gonorrhoeae appeared
(3). Gonococcal strains with reduced in vitro
susceptibility to fluoroquinolones (MIC,
0.125 µg/mL to 0.5 µg/mL) were first described
in the mid-1980s (4) and are now occurring
worldwide (5).
Fluoroquinolone-resistant N. gonorrhoeae
(ciprofloxacin MIC  >1.0 µg/mL) emerged
during the 1990s and became well established
in several Asian countries (6). In Japan, the
rate of ciprofloxacin resistance increased from
6.6% in 1993-1994 to 24.4% in 1997-1998 (7).
More recently, high-level resistance to
ciprofloxacin and reports of treatment failure
have appeared (8). Strains with ciprofloxacin
MICs of  >8.0 µg/mL were first isolated in 1994
(6) and are detected mostly in the Far East.
Two cases of gonococcal infection by strains
with an MIC of 16  µg/mL were recently re-
ported in the United States (9). Gonococcal
resistance to fluoroquinolones is associated
with mutations in the genes encoding DNA
gyrase (gyrA) and topoisomerase (parC) as well
as change in porin permeability and reduced
intracellular drug accumulation (6). In view of
the increasing resistance to fluoroquinolones,
ceftriaxone, cefixime, or spectinomycin is now
recommended if an infection was acquired in
Asia or other areas with known fluoroquinolone
resistance (9).
Our patient reported no travel to the Far
East, and his sex partner, who could not be
located for follow-up, was not Asian; her travel
history was unknown. The mode of transmis-
sion of this infection was fellatio. Condoms are
often not used in this form of intercourse, even
by those who regularly use condoms for genito-
genital sex, because of the mistaken belief that
infection is not spread through this form of
intercourse. It is now well established that oral
sex plays an important role in HIV transmis-
sion (10), and condoms should be used with any
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An Unusual Bacterium
Causing a Brain Abscess
To the Editor: Intracranial abscesses are an
important cause of illness and death in a
neurologic/neurosurgical unit. Early presump-
tive clinical diagnosis supported by radiologic
evidence (computerized axial tomography [CAT]
scan and magnetic resonance imaging) is the
mainstay of diagnosis (1). Abscess contents are
aspirated under stereotaxic guidance and
cultured to isolate causative organisms and
determine their antibiotic sensitivities. Organ-
isms isolated from brain abscesses are usually
streptococci, anaerobic and facultative gram-
negative bacilli, staphylococci, or pseudomonads
(2).
A 24-year-old male farmer came to us with
progressive headache, dizziness, and a low-
grade fever of 2 weeks’ duration. He had had a
pimple on his right cheek approximately 3
weeks before, which had discharged “bluish”
pus on forcible evacuation and subsequently
healed without treatment. No focal neurologic
signs were detected on physical examination.
Because an intracranial space-occupying lesion
was suspected, a lumbar puncture was with-
held. Later, a CAT scan of the patient’s head
revealed a right-sided temporoparietal space-
occupying lesion approximately 3 cm in diam-
eter, suggestive of a unilocular brain abscess.
The abscess was needle aspirated under stereo-
taxic guidance, and the pus was cultured
aerobically and anaerobically. After 24 hours of
aerobic incubation on MacConkey agar at 37°C,
a pure growth of violet-colored colonies appeared,
identified as Chromobacterium violaceum by
the 20E API system (Biomerieux, France).
Other initial laboratory findings were as
follows: blood leukocyte count, 16,200 cells/µL
(84% neutrophils, 15% lymphocytes, 1% eosino-
phils); erythrocyte sedimentation rate
(Westergren method), 22 mm/hour; C-reactive
protein concentration, 96 mg/L; and fasting
blood sugar concentration, 5.1 mmol/L. Blood
urea and C-reactive protein concentrations
after 3 weeks of antibiotic treatment were 4.6
mmol/L and <6 mg/L, respectively.
The organism was sensitive to imipenem
and ciprofloxacin and resistant to cefotaxime
and ceftriaxone, by the Stokes comparative
disk-diffusion antibiotic sensitivity testing
method (3). Ciprofloxacin (as lactate) was
administered intravenously, 400 mg twice a
day, for 4 weeks. Repeated CAT scans, clinical
symptoms, and serial C-reactive protein levels
indicated rapid regression of the abscess
followed by complete cure.
C. violaceum is a gram-negative bacillus
present in soil and aquatic environments of
tropical and subtropical countries or regions
such as Trinidad, Guyana, India, Malaysia,
Florida, and South Carolina. It is a bacterium of
low virulence, occasionally causing skin